219 related articles for article (PubMed ID: 28733185)
1. FDG-PET parameters as predictors of pathologic response and nodal clearance in patients with stage III non-small cell lung cancer receiving neoadjuvant chemoradiation and surgery.
Arnett AL; Packard AT; Mara K; Mansfield AS; Wigle DA; Haddock MG; Park SS; Olivier KR; Garces YI; Merrell KW
Pract Radiat Oncol; 2017; 7(6):e531-e541. PubMed ID: 28733185
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Value of the Volumetric Parameters of Dual-Time-Point
Okazaki E; Seura H; Hasegawa Y; Okamura T; Fukuda H
AJR Am J Roentgenol; 2019 Dec; 213(6):1366-1373. PubMed ID: 31509426
[No Abstract] [Full Text] [Related]
4. Utility of
Arnett ALH; Merrell KW; Macintosh EM; James SE; Nathan MA; Shen KR; Ravi K; Neben Wittich MA; Haddock MG; Hallemeier CL
J Thorac Oncol; 2017 Jan; 12(1):121-128. PubMed ID: 27569732
[TBL] [Abstract][Full Text] [Related]
5. Volume-Based Assessment With 18F-FDG PET/CT Improves Outcome Prediction for Patients With Stage IIIA-N2 Non-Small Cell Lung Cancer.
Hyun SH; Ahn HK; Ahn MJ; Ahn YC; Kim J; Shim YM; Choi JY
AJR Am J Roentgenol; 2015 Sep; 205(3):623-8. PubMed ID: 26295651
[TBL] [Abstract][Full Text] [Related]
6. FDG-PET in staging and restaging non-small cell lung cancer after neoadjuvant chemoradiotherapy: correlation with histopathology.
Ryu JS; Choi NC; Fischman AJ; Lynch TJ; Mathisen DJ
Lung Cancer; 2002 Feb; 35(2):179-87. PubMed ID: 11804691
[TBL] [Abstract][Full Text] [Related]
7. Serial assessment of FDG-PET FDG uptake and functional volume during radiotherapy (RT) in patients with non-small cell lung cancer (NSCLC).
Edet-Sanson A; Dubray B; Doyeux K; Back A; Hapdey S; Modzelewski R; Bohn P; Gardin I; Vera P
Radiother Oncol; 2012 Feb; 102(2):251-7. PubMed ID: 21885145
[TBL] [Abstract][Full Text] [Related]
8. Volume-based parameters measured by using FDG PET/CT in patients with stage I NSCLC treated with stereotactic body radiation therapy: prognostic value.
Satoh Y; Onishi H; Nambu A; Araki T
Radiology; 2014 Jan; 270(1):275-81. PubMed ID: 24029640
[TBL] [Abstract][Full Text] [Related]
9. 18F-FDG PET/CT of Non-Small Cell Lung Carcinoma Under Neoadjuvant Chemotherapy: Background-Based Adaptive-Volume Metrics Outperform TLG and MTV in Predicting Histopathologic Response.
Burger IA; Casanova R; Steiger S; Husmann L; Stolzmann P; Huellner MW; Curioni A; Hillinger S; Schmidtlein CR; Soltermann A
J Nucl Med; 2016 Jun; 57(6):849-54. PubMed ID: 26823566
[TBL] [Abstract][Full Text] [Related]
10. Greater reduction in mid-treatment FDG-PET volume may be associated with worse survival in non-small cell lung cancer.
Kong FS; Li L; Wang W; Campbell J; Waller JL; Piert M; Gross M; Cheng M; Owen D; Stenmark M; Huang KC; Frey KA; Ten Haken RK; Lawrence TS
Radiother Oncol; 2019 Mar; 132():241-249. PubMed ID: 30389239
[TBL] [Abstract][Full Text] [Related]
11. Detecting interval metastases and response assessment using 18F-FDG PET/CT after neoadjuvant chemoradiotherapy for esophageal cancer.
Stiekema J; Vermeulen D; Vegt E; Voncken FE; Aleman BM; Sanders J; Boot H; van Sandick JW
Clin Nucl Med; 2014 Oct; 39(10):862-7. PubMed ID: 25140549
[TBL] [Abstract][Full Text] [Related]
12. The maximum standardized uptake value of fluorodeoxyglucose positron emission tomography of the primary tumour is a good predictor of pathological nodal involvement in clinical N0 non-small-cell lung cancer.
Miyasaka Y; Suzuki K; Takamochi K; Matsunaga T; Oh S
Eur J Cardiothorac Surg; 2013 Jul; 44(1):83-7. PubMed ID: 23233074
[TBL] [Abstract][Full Text] [Related]
13. Volume-based parameters of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography improve outcome prediction in early-stage non-small cell lung cancer after surgical resection.
Hyun SH; Choi JY; Kim K; Kim J; Shim YM; Um SW; Kim H; Lee KH; Kim BT
Ann Surg; 2013 Feb; 257(2):364-70. PubMed ID: 22968069
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer.
Chen HH; Chiu NT; Su WC; Guo HR; Lee BF
Radiology; 2012 Aug; 264(2):559-66. PubMed ID: 22692034
[TBL] [Abstract][Full Text] [Related]
15. Significance of
Kim E; Wu HG; Keam B; Kim TM; Kim DW; Paeng JC; Kim HJ; Chang JH
Clin Lung Cancer; 2019 Jan; 20(1):e9-e23. PubMed ID: 30266585
[TBL] [Abstract][Full Text] [Related]
16. New positron emission tomography derived parameters as predictive factors for recurrence in resected stage I non-small cell lung cancer.
Melloni G; Gajate AM; Sestini S; Gallivanone F; Bandiera A; Landoni C; Muriana P; Gianolli L; Zannini P
Eur J Surg Oncol; 2013 Nov; 39(11):1254-61. PubMed ID: 23948705
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of SUVmax and metabolic tumor volume on 18F-FDG PET/CT in early stage non-small cell lung cancer patients without LN metastasis.
Yoo IeR; Chung SK; Park HL; Choi WH; Kim YK; Lee KY; Wang YP
Biomed Mater Eng; 2014; 24(6):3091-103. PubMed ID: 25227018
[TBL] [Abstract][Full Text] [Related]
18. 18F-FDG PET early response evaluation of locally advanced non-small cell lung cancer treated with concomitant chemoradiotherapy.
Usmanij EA; de Geus-Oei LF; Troost EG; Peters-Bax L; van der Heijden EH; Kaanders JH; Oyen WJ; Schuurbiers OC; Bussink J
J Nucl Med; 2013 Sep; 54(9):1528-34. PubMed ID: 23864719
[TBL] [Abstract][Full Text] [Related]
19. Application of novel quantitative techniques for fluorodeoxyglucose positron emission tomography/computed tomography in patients with non-small-cell lung cancer.
Wang D; Koh ES; Descallar J; Pramana A; Vinod SK; Ho Shon I
Asia Pac J Clin Oncol; 2016 Dec; 12(4):349-358. PubMed ID: 27550522
[TBL] [Abstract][Full Text] [Related]
20. FDG PET/CT for assessing the resectability of NSCLC patients with N2 disease after neoadjuvant therapy.
Kremer R; Peysakhovich Y; Dan LF; Guralnik L; Kagna O; Nir RR; Bar-Shalom R
Ann Nucl Med; 2016 Feb; 30(2):114-21. PubMed ID: 26613715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
